drug
Trelegy Ellipta
Marketedupdated 3mo agoby GlaxoSmithKline LLC
Approvedcommunity read0 votes
indications
investigational
COPDAsthma
all catalysts(0)
nothing on the calendar yet
Trials studying Trelegy Ellipta
- phase4Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations
- phase4ANTES B+ Clinical Trial
- —A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- —A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 18, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Apr 11, 2031patentUS 8746242*PED4.6y
- Apr 11, 2031patentUS 8746242*PED4.6y
- Nov 29, 2030method-of-use (U-3202)US 110902944.3y
- Nov 29, 2030formulationUS 123969864.3y
- Nov 29, 2030formulationUS 123969864.3y
- Nov 29, 2030formulationUS 97507264.3y
- Nov 29, 2030formulationUS 97507264.3y
- Oct 11, 2030formulationUS 87462424.1y
- Oct 11, 2030formulationUS 87462424.1y
- Sep 8, 2030patentUS 8534281*PED4.0y
- Sep 8, 2030patentUS 8534281*PED4.0y
- Mar 8, 2030formulationUS 85342813.5y
- Mar 8, 2030formulationUS 85342813.5y
- Dec 18, 2027compositionUS 74888271.3y
- Dec 18, 2027compositionUS 74888271.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that